1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1670
  5. Art Unit 1671
  6. Examiner Blumel

Examiner Blumel Benjamin P

1671-BLUMEL-BENJAMIN-P

Employment Information

Art Unit:1671 — Drug, bio-affecting and body treating compositions
Group:1670 — Virology, Viral Immunology, And Viral Pathogens, Neurology, Receptors, Cytokines & Recombinant Hormones and Immunoassays and related devices
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
514 — Drug, bio-affecting and body treating compositions
422 — Chemical apparatus and process disinfecting, deodorizing, preserving, or sterilizing
506 — Combinatorial chemistry technology: method, library, apparatus
Phone:(571) 272-4960
Email:benjamin.blumel@uspto.gov
Location:VA 22314
Title:Pat Examnr (Biolgy)
Service:20 years
Grade:GS-14

Grant Rate and Difficulty Ranking

50
3-Year Grant rate: 77% over 384 cases
Difficulty: Medium
Difficulty Percentile: 50th

With Examiner Blumel, you have a 77% chance of getting an issued patent by 3 years after the first office action. Examiner Blumel is a medium examiner and in the 50th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Blumel, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1671

Examiner Blumel's grant rate is higher than that of Art Unit 1671 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Blumel 2.0
Art Unit 1671 1.3

Interview Benefit

Grant Rate without Interview

Examiner Blumel has granted 231 of 307 cases without any applicant-requested interviews for a grant rate of 75%.

Grant Rate with Interview

Examiner Blumel has granted 63 of 77 cases with at least one applicant-requested interview for a grant rate of 82%.

Interview Benefit

With Examiner Blumel, conducting an interview increases your chance of getting a patent granted by 9%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18024538 Recombinant Sars-Cov-2 Spike Protein Subunits, Expression And Uses Thereof Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
18014167 Crispr-Cas-Based Detection Of Sars-Cov-2 Using Recombinase Polymerase Amplification Abandoned View
17834340 Methods And Compositions For Treating Cancer Patented View
18009022 Fusion Protein Of Pentamer And Gb Of Cytomegalovirus, And Vaccine Containing Said Fusion Protein Patented View
17756971 Pharmaceutical Compositions Comprising Cabotegravir Abandoned View
17251736 Nucleic Acid Aptamers Targeting Lymphocyte Activation Gene 3 (Lag-3) And Uses Thereof Abandoned View
16210750 Methods And Compositions Comprising Cationic Lipids For Stimulating Type 1 Interferon Genes Patented View
18635203 Tropical Disease Vaccines Abandoned View
17616137 Live Attenuated Universal Influenza Virus Vaccines, Methods And Uses Thereof Abandoned View
18350646 Production Of Flu Vaccine In Myceliophthora Thermophila Abandoned View
17259885 Methods For Generating Pan-Epitopic Immunogens Of Influenza H3 Virus, Compositions And Methods Of Use Thereof Abandoned View
17041792 Methods Of Generating Broadly Protective Vaccine Compositions Comprising Neuraminidase Patented View
17782951 Methods For Identifying Viral Infections And For Analyzing Exosomes In Liquid Samples By Raman Spectroscopy Abandoned View
16753657 Microbiota Sequence Variants Of Tumor-Related Antigenic Epitopes Abandoned View
16098834 Influenza Mrna Vaccines Patented View
18654557 Compositions For Use In Treatment Of Acne Patented View
18511859 Boosting Immunogenicity Of Vaccines Using Saponins And Agonists Of The Intracellular Stimulator Of Interferon Genes Pathway Abandoned View
18425919 Neutralizing Anti-Influenza A Antibodies And Uses Thereof Patented View
18500926 Methods For Purification Of Recombinant Aav Vectors Abandoned View
18665250 Methods Of Detection And Removal Of Rhabdoviruses From Cell Lines Patented View
18322679 Parenteral Norovirus Vaccine Formulations Abandoned View
18481345 Optimized Host/vector System For Producing Protective Mono- And Multivalent Subunit Vaccines On The Basis Of The Yeast Kluyveromyces Lactis Patented View
18448089 Biological Therapeutics For Infection-Relating Disorders Or Conditions Abandoned View
16982356 Method For Determining Vaccine Efficacy In An Individual And Means Therefore Abandoned View
17931017 Recombinant Nucleic Acid Construct Encoding Influenza Peptides And Compositions Abandoned View
18148077 Gene Therapy For Ceroid Lipofuscinoses Patented View
17428921 Stabilized 9 And 10 Segmented Influenza Viruses As A Vaccine Platform And Methods Of Making And Using Same Patented View
17510930 Anti-Dengue Vaccines And Antibodies Patented View
17058379 Antigenically Stealthed Oncolytic Viruses Patented View
18048827 Dna Molecules Producing Custom Designed Replicating And Non-Replicating Negative Stranded Rna Viruses And Uses There Of Abandoned View
18348323 Novel Severe Fever With Thrombocytopenia Syndrome Virus Patented View
17835830 Influenza Viruses With Mutant Pb2 Gene Segment As Live Attenuated Vaccines Patented View
18368968 Single Cycle Replicating Adenovirus Vectors Abandoned View
16966345 Pseudorabies Virus For Treating Tumors Patented View
17458712 Immunogenic Composition Patented View
17246955 Zika Virus Treatment Of Cd24-Positive Tumors And Diseases Associated With Abnormal T Cell Activation And Treating Or Preventing Zika Virus Infections Patented View
18115253 Lateral Flow Assays For Non-Diagnostic Analytes Abandoned View
17535998 Methods And Systems For Determining Viruses In Biological Samples Using A Single Round Based Pooling Abandoned View
17527524 Methods And Kits For The Diagnosis Of Influenza Patented View
17252638 Mosaic Influenza Virus Hemagglutinin Polypeptides And Uses Thereof Patented View
18063902 Method Of Treating Influenza A Patented View
17590173 Combination Vaccine Patented View
17572465 Seasonal Rna Influenza Virus Vaccines Patented View
17732141 Modified Immunization Vectors Patented View
16595980 Alphavirus-Based Replicons For Administration Of Biotherapeutics Patented View
18801071 Nucleic Acid Vaccines Abandoned View
18941809 Nucleic Acid Vaccine Against The Sars-Cov-2 Coronavirus Patented View
18298233 Method To Improve Virus Filtration Capacity Abandoned View
17737532 Infectious Disease Vaccines Abandoned View
18163145 Fcrn-Targeted Mucosal Vaccination Against Influenza Infections Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.